Angle (AGL.L) 69p £99.72m The liquid biopsy company, announced that the first phase of its ovarian cancer clinical verification study has reported positive results. The pre-study, undertaken by Dr. Richard Moore and colleagues at the University of Rochester Medical Center Wilmot Cancer Institute (Rochester), was designed to evaluate the use of ANGLE's modified and further optimised ParsortixTM and HyCEADTM Ziplex® platfor-ms as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass, in a clinical setting and with clinical samples. The pre-study results demonstrate that the optimisation of the sample-to-answer molecular solution has been successful, paving the way to initiate the 200 subject ovarian cancer clinical verification study of patients who are presenting with a pelvic mass and scheduled for surgery. A positive outcome from the clinical verification study would support ANGLE's plans to launch a clinical assay for the detection of ovarian cancer in women with an abnormal pelvic mass. This study is expected to start in early Q3 CY19 and is projected to complete in Q1 CY20.
Angle Plc (AGL.L) Announced that the first phase of its ovarian cancer clinical verification study has reported positive results. The pre-study results demonstrate that the optimisation of the sample-to-answer molecular solution has been successful, paving the way to initiate the 200 subject ovarian cancer clinical verification study of patients who are presenting with a pelvic mass and scheduled for surgery. This study is expected to start in early Q3 CY19 and is projected to complete in Q1 CY20.
RNS Number: 1523 B Angle PLC 05 June 2019 ANGLE plc. SUCCESSFUL COMPLETION OF OVARIAN CANCER PRE-STUDY. Pre-study demonstrates ANGLE's optimised sample-to-answer molecular solution with patient samples.
Angle Plc (AGL.L) Announced positive results from its Parsortix FDA clinical study for metastatic breast cancer. The Study has achieved its primary objective to demonstrate the ability of the Parsortix system to capture and harvest cancer cells from the blood of a significant proportion of metastatic breast cancer patients.
RNS Number: 6723 A Angle PLC 31 May 2019 ANGLE plc. POSITIVE RESULTS FROM FDA CLINICAL STUDY. Analytical studies ongoing to support FDA submission.
RNS Number: 1692 X Angle PLC 26 April 2019 ANGLE plc. BREAKTHROUGH RESEARCH USING THE PARSORTIX SYSTEM DISCOVERS ROLE OF BODY'S OWN IMMUNE SUPPRESSOR CELLS IN PROMOTING CANCER METASTASIS. The research, led by Professor Dario Marchetti at the Biomarker Research Program, Houston Methodist Research Institute in conjunction with the Center for Precision...
Angle Plc (AGL.L) Announced that top US cancer centre, the University of Texas MD Anderson Cancer Center has developed a new technique for assessing the metastatic potential of breast cancer using the company's ParsortixTM system. The technique Transmembrane Receptor Dynamics (TReD) measures the dynamics of cytoskeletal structure and mechanical properties of live cancer cells held within the microfluidic Parsortix cassette using an optical interrogation technique. The development work has been published in the peer-reviewed publication, Nature. The publication states that the TReD approach can serve "as a new biophysical marker to probe the metastatic potential of cancer cells and even to monitor the transition of metastasis". This offers the potential to differentiate highly invasive cancer cells from non to less-invasive cancer cells allowing more personalised treatment to be offered to the patient.
RNS Number: 5546 W Angle PLC 18 April 2019. MD ANDERSON DEVELOPS NEW TECHNIQUE FOR ASSESSING CANCER USING PARSORTIX. Study published in leading peer-reviewed publication Nature.
Angle Plc (AGL.L) Announced that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using the company's Parsortix system, which may give advance warning of relapse in non-small cell lung cancer (NSCLC). The study is being conducted by the Hellenic Oncology Research Group (Hellenic) lead by the Principal Investigators, Associate Professor Athanasios Kotsakis and Professor Vassilis Georgoulias of the IASO General Hospital in Athens, Greece and is investigating both ctDNA (circulating tumor DNA, fragments of dead cancer cells) and CTCs. The CTC evaluation is being undertaken by the University of Athens lead by Professor Evi Lianidou. Parsortix is the only CTC system being used in the study.
RNS Number: 9770 V Angle PLC 12 April 2019. The study is being conducted by the Hellenic Oncology Research Group lead by the Principal Investigators, Associate Professor Athanasios Kotsakis and Professor Vassilis Georgoulias of the IASO General Hospital in Athens, Greece and is investigating both ctDNA and CTCs. The CTC evaluation is being undertaken by the...
Angle Plc (AGL.L) Announced that its ParsortixTM system has been showcased by a number of customers in poster presentations at the American Association for Cancer Research conference (AACR) 2019, in Atlanta, Georgia, United States from 29 March to 3 April 2019. In addition, the company presented detailed performance data from the optimisation of its ovarian cancer assay for both its Parsortix and HyCEAD Ziplex systems at the conference.
RNS Number: 0679 V Angle PLC 04 April 2019. ANGLE plc, a world-leading liquid biopsy company, today announces that its Parsortix TM system has been showcased by a number of customers in poster presentations at the American Association for Cancer Research conference 2019, in Atlanta, Georgia, United States from 29 March to 3 April 2019.. Work by the University of...
RNS Number: 3766 S Angle PLC 11 March 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Angle (AGL.L) 59.5p £85.4m T h e “ l i q u i d b i o p s y company, announced that enrolment for its Parsortix FDA clinical study for metastatic breast cancer is now complete. We are grateful to the four leading US cancer centres, the University of Texas MD Anderson Cancer Center, the University of Southern California Norris Cancer Center, the University of Rochester Wilmot Cancer C e n t e r , a n d t h e Northwestern University Robert H Lurie Cancer Center for their efforts in completing enrolment of all of the required 400 evaluable subjects. Downstream analyses of the samples will now be completed by the centres and the evaluation of the results from the clinical study and the ongoing analytical studies will be completed with the aim of a submission to the FDA midyear, as planned. The timing of FDA regulatory clearance is dependent on the FDA's review and response to our submission. As we are following a de-novo process for the first p o t e n t i a l F D A clearance1 of a system intended for harvesting cancer cells from patient blood for subsequent analysis, it is not possible to predict with certainty how long this process will take.”
Angle Plc (AGL.L) Announced that the enrolment for its Parsortix FDA clinical study for metastatic breast cancer is now complete.
RNS Number: 1007 S Angle PLC 07 March 2019. ENROLMENT COMPLETE FOR FDA CLINICAL STUDY. Submission to the FDA expected mid-year as planned.
RNS Number: 3554 R Angle PLC 28 February 2019 ANGLE plc. FIRST SUBJECTS ENROLLED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY. Study to confirm the combination of ANGLE's Parsortix system with its new HyCEAD Ziplex platform as sample-to-answer for accurate pelvic mass triage.
RNS Number: 9337 Q Angle PLC 25 February 2019. ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that one of its leading customers, the Disseminated Cancer Cell Network, Duesseldorf, an interdisciplinary team of researchers and clinicians whose goal is to better understand systemic disease in cancer and to improve individualised...
Angle (AGL.L) 57p �79.64m The “liquid biopsy company, announced that its ParsortixTM system has been utilised in further ground-breaking cancer research into CTC clusters demonstrating that the patient's own immune cells (neutrophils) may actively help the process of metastasis by which the cancer spreads. The new research, led by Professor Nicola Aceto at the Cancer Metastasis Laboratory, University of Basel, Switzerland (Basel) has been published as a peer-reviewed publication in the prestigious journal Nature. The publication follows other research on CTC clusters led by Professor Aceto, recently published in the journal Cell, which identified drugs which dissociated highly metastatic CTC clusters resulting in a near total elimination of metastasis in animal models. The research published in Nature identified a subset of circulating tumor cell clusters (CTC clusters, a group of cancer and other cells tethered together as a single mass) using ANGLE's Parsortix system, in which the cluster contains one or more neutrophil (a CTC-neutrophil cluster).
Angle Plc (AGL.L) Announced that its Parsortix system has been utilised in further ground-breaking cancer research into CTC clusters demonstrating that the patient's own immune cells (neutrophils) may actively help the process of metastasis by which the cancer spreads. The new research, led by Professor Nicola Aceto at the Cancer Metastasis Laboratory, University of Basel, Switzerland has been published as a peerreviewed publication in the prestigious journal Nature. The publication follows other research on CTC clusters led by Professor Aceto which identified drugs which dissociated highly metastatic CTC clusters resulting in a near total elimination of metastasis in animal models
ANGLE Plc
AGL.L
ANGLE Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    143.49M

Classification

Market Indices-

Locations

HQ
The Surrey Research Park
3 Frederick Sanger Road
Guildford
GU2 7YD
Watchlist